Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02609139
Recruitment Status : Completed
First Posted : November 20, 2015
Last Update Posted : May 9, 2016
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This is a Phase 1, open-label, single-dose, within-cohort randomized, 2-way crossover study to evaluate the PK of orally administered PF-06650833 modified release tablets under fasted and high fat meal fed conditions in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: PF-06650833 Phase 1

Detailed Description:
This is the third study of PF-06650833. The goals of the study are to assess the PK in healthy subjects of single doses of modified release (MR) tablets of PF-06650833 when orally administered under fasting and high fat meal fed conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, Open Label, Single‑Dose, Within Cohort Randomized, 2‑Way Crossover Study To Evaluate The Pharmacokinetics Of A Modified Release Formulation Of Pf‑06650833 Under Fasting And Fed Conditions In Healthy Adult Subjects
Study Start Date : November 2015
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Arm Intervention/treatment
Experimental: <=400mg Modified Release Tablets, Fasted
Up to 400 mg PF-06650833 modified release tablets administered under fasted conditions
Drug: PF-06650833
Up to 400mg modified release tablets administered under fasted conditions

Experimental: 100mg Modified Release Tablets, Fasted
100 mg PF-06650833 modified release tablets administered under fasted conditions
Drug: PF-06650833
100mg modified release tablet administered under fasted conditions

Experimental: 20mg Modified Release Tablets, Fasted
20 mg PF-06650833 modified release tablets administered under fasted conditions
Drug: PF-06650833
20mg modified release tablet administered under fasted conditions

Experimental: <= 400mg Modified Release Tablets, Fed
Up to 400 mg PF-06650833 modified release tablets administered with high fat meal food intake
Drug: PF-06650833
Up to 400mg modified release tablets administered with high fat meal food intake

Experimental: 100mg Modifed Release Tablets, Fed
100 mg PF-06650833 modified release tablets administered with high fat meal food intake
Drug: PF-06650833
100mg modified released tablet administered with high fat meal food intake

Experimental: 20mg Modified Release Tablets, Fed
20 mg PF-06650833 modified release tablets administered with high fat meal food intake
Drug: PF-06650833
20 mg modified release tablet administered with high fat meal food intake




Primary Outcome Measures :
  1. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Maximum plasma concentration (Cmax) of PF-06650833

  2. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Area under the plasma concentration versus time curve from time zero to the time of the last quantifiable concentration (AUClast) of PF-06650833

  3. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Area under the plasma concentration versus time curve from time zero extrapolated to infinite time (AUCinf) of PF-06650833 (if data permit)

  4. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Dose-normalized maximum plasma Cmax (Cmax(dn)) of PF-06650833

  5. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Dose-normalized area under the plasma concentration versus time curve from time zero to the time of the last quantitfiable concentration (AUClast(dn)) of PF-06650833

  6. Plasma pharmacokinetic parameters of PF-06650833 (if data permit) [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Dose-normalized area under the plasma concentration versus time curve from time zero extrapolated to infinite time (AUCinf(dn)) of PF-06650833 (if data permit)


Secondary Outcome Measures :
  1. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Time post dose associated with the maximum plasma concentration (Tmax) of PF-06650833

  2. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Terminal half life of PF-06650833 (if data permit)

  3. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Lag time of plasma concentration of PF-06650833 (if data permit)

  4. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Absorption rate constant of PF-06650833 (Ka) (if data permit)

  5. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Apparent Clearance (CL/F) of PF-06650833 (if data permit)

  6. Plasma pharmacokinetic parameters of PF-06650833 [ Time Frame: Baseline for up to Day 14 (0 to +1) postdose ]
    Apparent Volume of Distribution (Vz/F) of PF-06650833 (if data permit)

  7. Treatment emergent adverse events and withdrawals [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events

  8. Vital signs [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Changes from baseline in vital signs (blood pressure, pulse rate, and respiratory rate)

  9. Electrocardiogram parameters [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Changes from baseline in electrocardiogram parameters (standard 12-lead ECG)

  10. Clinical laboratory measurement [ Time Frame: Baseline to up to Day 14 (0 to +1) postdose ]
    Changes from baseline in clinical laboratory values



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy female subjects of non childbearing potential and/or male subjects, between the ages of 18 and 55 years
  2. BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  3. Personally signed and dated Informed Consent
  4. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  1. Clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
  2. Any condition possibly affecting drug absorption
  3. Positive urine drug screen.
  4. Heavy smokers
  5. History of regular heavy alcohol consumption within 6 months of Screening.
  6. Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives
  7. Screening supine blood pressure <=100 mm Hg (systolic) or<=50 mm Hg (diastolic) or>=140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of supine rest.
  8. Screening pulse (HR) >100 bpm after at least 5 minutes of rest.
  9. Single supine 12 lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec at Screening.
  10. Abnormal chest X ray
  11. History of TB or active or latent or inadequately treated infection, positive Quantiferon TB test.
  12. History of hepatitis or positive testing for human HIV,HepBsAg, HepBc Ab or HCVAb
  13. Any medical history of disease [ie, Gilbert's disease] that has the potential to cause a rise in total bilirubin over the ULN
  14. Clinical laboratory abnormalities including:

    • Creatine kinase >1.2 X ULN;
    • CK MB > ULN;
    • Serum myoglobin >1.2 X ULN;
    • Cardiac Troponin I (cTn I) > ULN of the laboratory reference range;
    • Serum aspartate transaminase (AST) or alanine transaminase (ALT) >=2 x ULN, total serum bilirubin >=1.5 mg/dL;
    • Subjects with benign ethnic neutropenia;
    • Hemoglobin <=14 gm/dl (males) and <=13 gm/dL (females).
  15. Nursing female subjects; male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for 28 days after the last dose of investigational product or longer based upon the compound's half life characteristics.
  16. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product until discharge from the study at the end of Period 2.

    Herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of investigational product. Acetaminophen/paracetamol should not be used. As an exception, ibuprofen may be used at doses of 200 to 400 mg orally every 6 hours as needed for up to 3 of 7 consecutive days.

  17. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  18. History of sensitivity to heparin or heparin induced thrombocytopenia.
  19. History of cancer (other than treated basal cell and squamous cell carcinoma of the skin) in the previous 5 years.
  20. Previous exposure to PF 06650833.
  21. Unwilling or unable to comply with the Lifestyle guidelines
  22. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees directly involved in the conduct of the study.
  23. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02609139


Locations
Layout table for location information
United States, Connecticut
New Haven Clinical Research Unit
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT02609139    
Other Study ID Numbers: B7921004
IRAK4 MR PK Study ( Other Identifier: Alias Study Number )
First Posted: November 20, 2015    Key Record Dates
Last Update Posted: May 9, 2016
Last Verified: May 2016